Iqvia price target lowered to $211 from $261 at Stifel

Stifel lowered the firm’s price target on Iqvia (IQV) to $211 from $261 and keeps a Buy rating on the shares. President Trump has discussed plans for tariffs on pharma imports, and Iqvia’s client base is overwhelmingly pharma and is skewed towards large and mid-sized pharma companies, the analyst tells investors in a research note. The firm envisions tariffs impacting Iqvia from clients pulling back on discretionary spend from the cost shock of tariffs and the potential for delayed decision-making in the market from more portfolio re-evaluation.